BACKGROUND {#sec0005}
==========

Parkinson's disease (PD) is the second most common neurodegenerative disease worldwide, yet remains without a cure, and available treatments are widely agreed to have significant limitations in the long term. Despite its heterogeneity, the core pathology that is common to all patients is the loss of dopamine (DA) neurons in the midbrain. These midbrain DA neurons send their projections to the striatum where they release DA, which is needed to accurately modulate initiation and execution of movement. As the DA neurons degenerate, lower DA levels in the striatum cause the characteristic motor symptoms of the disease. The most common treatment provided today is based on enhancing the activity of the nigro-striatal pathway with DA-modulating therapies, thereby increasing the striatal DA levels, and thus improving the motor impairment associated with the disease. While these dopaminergic (DAergic) treatments are highly effective initially, they eventually lead to the development of a number of troublesome side effects such as on-off phenomena, and L-dopa induced dyskinesia (LID). Moreover, their administration may be limited by side effects that can include hallucinations and other psychiatric problems \[[@ref001]\]. This is explained by temporally and spatially dysregulated DA delivery resulting from DAergic intake. A better way of treating the DA responsive aspects of PD would therefore be to target the DA replacement locally at the site of action (i.e., the striatum) and to regulate the release as closely as possible to physiological conditions.

Historically, and in the majority of current efforts underway or planned, cell replacement therapy for PD has been focused upon the characteristic striatal DAergic deficit, based on the idea that replacing the lost DA neurons with new healthy cells would result in DA release only where it is needed, and with a smooth temporal profile as close to physiologic delivery as possible. The approach was pioneered in Lund over 30 years ago, using fetal cells obtained from the midbrain of aborted embryos and, since then, a few hundred patients have received such transplants. Other donor cell sources tested include autologous adrenal medulla and carotid body tissue (dopamine-producing tissues requiring invasive procedures for harvest) that in clinical trials resulted in poor cell survival, and variable and modest benefit at best \[[@ref002]\]. More recently, retinal pigment epithelial cells (RPE) delivered in a gelatin sphere (Spheramine^®^) provided no significant benefit compared with controls in a sham surgery controlled clinical trial \[[@ref004]\], likely related to poor cell survival \[[@ref005]\]. However, studies of fetal cell transplantation in PD have provided proof-of-principle that effective and long term repair can be achieved by cell transplantation \[[@ref006]\], and in some cases, study participants were able to reduce or stop their anti-PD medications \[[@ref007]\]. Unfortunately, despite some successes the overall outcomes have been highly variable. Although some patients have showed a restoration to "normality" of striatal DAergic innervation along with long term clinical benefit, others have had minor or no effect of their transplants, and some even experienced debilitating side effects, in particular graft induced dyskinesia (GID) \[[@ref006]\]. Since at least some of the variability is likely from differences in the subjects transplanted, different surgical approaches, and different outcome measures, a new clinical trial called TRANSEURO using fetal cells is underway, with an optimized design that includes a study cohort based upon careful analysis of previous trials, standardized and reproducible surgical placement protocols, and with long term follow up using robust outcome measures (<http://www.transeuro.org.uk>). This should address many of the problems noted above but, unfortunately, lack of uniformity in fetal tissue together with limited access means that it can never become a main line therapy.

In the future, use of cells derived from renewable and bankable sources that can meet the demand of large patient populations is needed. The most promising such cell source today is pluripotent stem cells, from which authentic and functional DA neurons now can be obtained under conditions compliant with use in patients \[[@ref008]\]. Stem cell-based therapies for PD are now rapidly moving towards use in clinical trials and several academic as well as industry efforts are well on their way to initiate clinical trials \[[@ref009]\].

In this review, we discuss potential advantages and limitations of cell-based therapies as they are being tested or are envisaged for PD today, and present speculations on how a number of shortcomings and limitations might be mediated by an increased understanding of the disease itself and new approaches in next-generation transplantation-based cell therapies ([Table 1](#jpd-8-jpd181488-t001){ref-type="table"}).

###### 

Summary of the three types of cell sources discussed in this review. Advantages of stem cells versus fetal tissue as donor cell source

  -----------------------------------------------------------------------------------------------------------------------------------
    **Fetal cell replacement:**
    Obtained from human fVM
    Has proven to be effective in patients
    Effective immunosuppression that allow long term graft survival exists
    **Current stem cell-based approach:**
    Uniform population of cells
    High yield of DA progenitors
    Readily available
    May be cryopreserved
    Preclinical safety, efficacy and dosing studies may be performed in animals with the same cells as for clinical transplantation
    Predicted lower risk of complications of graft-induced dyskinesia
    **Future stem cell-based approach:**
    May produce and deliver a combination of therapeutic cell types
    May genetically engineer to enhance safety or therapeutic role
    May control neurite outgrowth and synaptogenesis
    Possibility to plan more individualized/spatially appropriate surgical delivery
    May allow treatment with patients own cells or matched donors
  -----------------------------------------------------------------------------------------------------------------------------------

TOWARDS A MORE ROBUST CLINICAL OUTCOME {#sec0010}
======================================

Data from published clinical trials performed to date using fetal cells is promising, but raises concern about heterogeneity of clinical outcomes reported. Much of this can be related to inconsistency in: i) cell preparation, cell number and cell composition; ii) patient selection; iii) method and duration of immunosuppression; iv) outcome measures and study duration; v) surgical delivery (critically reviewed by Barker and colleagues \[[@ref006]\]). While optimized clinical trial characteristics are key to the ongoing TRANSEURO study as noted above, standardized and sufficiently quality controlled cell preparations simply cannot be achieved with fetal cells. The age of the embryos varies and tissue dissection, no matter how careful, may result in samples with variable content of not only DA neuron progenitors, but also precursor cells for serotonergic and other neurons, glial cells, and elements of vasculature. With stem cells however, it is now possible to make very large quantities of uniform transplantable cells that can be cryopreserved \[[@ref010]\]. This means that rigorous quality control, as well as efficacy and safety testing, may be performed on the identical cell preparation that will subsequently be transplanted into patients ([Fig. 1](#jpd-8-jpd181488-g001){ref-type="fig"}b). It also means that each patient in a trial will receive an identical cell preparation in a precisely specified amount, which is expected to reduce the variation in outcome significantly. Moreover, the availability of vials of cryopreserved cells that can be thawed at any time will greatly simplify surgical planning, and increase access to such therapies for study participants and eventually the PD community. Finally, although there remains much to learn, the existence of banks of cryopreserved cells not only opens the possibility for an "off the shelf" therapeutic that could be broadly available and distributed, but would also be the first step to a deeper understanding of therapeutic performance across varying patient types, that could result in being able to individualize dopamine neuron dose and cell delivery target in a heterogeneous patient population.

![Stem cells today and in the future. When using fetal cells for transplantation (a), tissue is collected and transplanted without the possibility for banking or quality assessment of the cells prior to transplantation. In contrast, DA progenitors derived from hESCs (b) can be banked and stored, allowing for extensive pre-clinical safety and efficacy testing of the cells prior to transplantation. Pluripotent stem cells can be obtained from pre-implantation blastocyst (c) or via reprogramming from fibroblasts (d) and differentiated into DA progenitors that mature into fully functional DA neurons after transplantation. In the case of iPSCs, they can be reprogrammed from matched donors or from the patients themselves. In the future, directly converted cells (e) or cells reprogrammed by viral injection into the brain (f) are attractive alternatives.](jpd-8-jpd181488-g001){#jpd-8-jpd181488-g001}

AVOIDING GRAFT INDUCED DYSKINESIA {#sec0015}
=================================

Aside from variable clinical benefit for key features of PD, there have also been concerns over variable tolerability, given that a subset of patients developed off-medication-state graft-induced dyskinesia (GID) after fetal cell transplantation \[[@ref012]\]. The reasons behind emergence of GID are still debated but discussion has focused upon the presence of serotonergic (5HT) neurons in the graft, or "hot spots" of engrafted DA neurons resulting from uneven surgical delivery and/or growth.

5HT neurons have their embryological origin adjacent to the midbrain DA neurons and are co-mingled in the caudal region of the ventral midbrain. Thus it is not possible to completely remove them when dissecting and preparing fetal tissue for transplantation. These 5HT neurons in the graft might then result in dysregulated striatal DA contributing to dyskinesia. Moreover, not only is the presence of 5HT neurons in the graft a factor, but an elevated ratio of 5HT/DA neurons is also likely important as a cause of GID \[[@ref014]\]. Therefore, removing donor 5HT neurons is expected to reduce the risk of GID significantly if not completely. From a stem cell source of neurons it is possible to more finely and precisely control cell differentiation and therefore to obtain cell preparations that are completely devoid of any 5HT neurons or precursors that might lead to GID. Moreover, with a large quantity of cells available, cell sorting strategies can be used to enrich for desired cells or remove unwanted contaminations.

GID may also arise from uneven spread of DA neurons after cell transplantation, resulting in DA "hot spots". In addition to surgical delivery considerations, donor tissue characteristics may also contribute to hot spots. It is well known that fetal cells of different stages generate a variable number of neurons with varying innervation capacity \[[@ref015]\], but it is not possible to predict DA yield or innervation capacity of such a tissue sample in the time frame necessary prior to grafting. Each patient undergoing fetal cell transplant receives a unique mix of cells from embryos at varying ages, and so DA hot spots cannot be securely eliminated. In contrast, when working with stem cell preparations, a major advantage is that aliquots of the same cells to be used in patients can be tested for phenotype, function, and outgrowth capacity in pre-clinical animal models ([Fig. 1](#jpd-8-jpd181488-g001){ref-type="fig"}b), and this assessment can then be used to guide the number of cell deposits and tracts to be used for an optimal dispersal of cells to result in an even innervation of the putamen that is necessary for a good effect with minimal side effects. In the future, it may even be possible to introduce the cells with some type of matrix that would promote or guide outgrowth and innervation.

ARE HUMAN EMBRYONIC STEM CELLS THE BEST OPTION? {#sec0020}
===============================================

Human embryonic stem cells (hESCs) are actively being developed for clinical trials in PD by both academia and industry, and are expected to reach clinical trial later this year. The use of hESCs seems like a logical choice, given the richness of pre-clinical data supporting their use, and that a number of hESC lines meeting Good Manufacturing Practice (GMP) standards are already available.

However, there are other potential cell sources being actively explored as potential future treatments ([Fig. 1](#jpd-8-jpd181488-g001){ref-type="fig"}c-e). The ability to reprogram cell fate using defined combinations of transcription factors \[[@ref017]\] has transformed the field of regenerative medicine and opened up the possibility to obtain induced pluripotent stem cells (iPSCs) either from patients themselves or from immunologically matched donors \[[@ref018]\]. This type of pluripotent stem cell responds to the same patterning cues as the hESCs and generates DA neurons of equal quality \[[@ref020]\]. A recent study also showed that HLA matched grafting can be advantageous for cell survival and function \[[@ref024]\]. However, the use of cells from immunologically matched donors further increases complexity and cost of stem cell based therapies. Nevertheless, iPSCs have already been used in clinical trials for macular degeneration \[[@ref025]\] and are being actively pursued for PD \[[@ref026]\].

In 2010, it was reported that skin cells could be directly reprogrammed into neurons without passing through a stem cell intermediate \[[@ref027]\]. This type of direct conversion is generally considered as safer, since the pluripotent stage is completely avoided. Today, it is possible to generate DA neurons via direct conversion of human skin cells \[[@ref028]\], but they do not yet survive and function as well after transplantation as stem cell-derived DA neurons \[[@ref030]\]. An interesting extension of direct cell fate conversion is to reprogram cells directly in the brain by injection of the conversion genes instead of cells. This has been achieved in rodent models and in transplanted human fibroblasts \[[@ref031]\], but the precise dopamine identity of the *in vivo* reprogrammed neurons is still unclear \[[@ref032]\]. Given time however, we predict that cellular conversion will become more and more refined \[[@ref035]\], and it is not out of bounds to speculate that patients will be treated with healthy versions of their own cells in the future.

PERSPECTIVE AND FUTURE GOALS {#sec0025}
============================

Present efforts in cell replacement in PD are overwhelmingly focused on dopaminergic replacement and control of movement. The first generation of stem cell-derived DA neurons now in the pipeline is predicted to perform at least at an equivalent level to human fetal cells, but in a more robust and reproducible manner, providing a stable, expandable, and readily accessible cell source for transplantation. As such the therapy is expected to provide a better way of treating the DA responsive features of PD using a targeted, physiological delivery of DA to the striatum, but it is not a disease modifying treatment, nor a cure.

Many questions remain to be addressed.•While immunosuppression is planned for transplantation of unmatched cells, the optimal approach remains unproven. Use of iPS-derived cells, that will provide wholly or partially matched donor cells for transplantation is already being addressed, but whether (and what) immunosuppression is truly required in the case of partially matched donors remains to be determined.•PD pathology is not cell-autonomous, and the spread of pathology potentially affecting graft function is an oft-repeated although unsubstantiated objection to cell therapy. While current evidence supports absence of any major effect, it does raise the question of whether a combinatorial therapy comprising grafting and, for example, a biologic or small molecule to abrogate spread of alpha-synuclein pathology would be desirable.•It is believed that obtaining even innervation from the graft would be advantageous, and so interventions that could promote neurite outgrowth and synaptogenesis need to be explored.•A major area for research is whether and how genetic manipulation of cells for transplant could enhance therapeutic safety and impact, for example including a "suicide switch" in case of overgrowth, or incorporating a mechanism to deliver neuroprotective species, to combat further cell dysfunction in the host environment. Gene editing of the cells can also be done so that the graft function can be modulated using DREADDS (Designer Receptors Exclusively Activated by Designer Drugs) or optogenetics \[[@ref036]\].•Despite the focus of this article on motor function, dopamine is known to impact upon various important non-motor aspects of PD, including learning, attention, reward, mood, and sleep. Is it possible that engrafting dopamine-producing donor cells could provide non-motor benefits? This idea has gained traction with recent findings that intrastriatal grafts of embryonic ventral mesencephalic tissue lead to improvements in behavioral testing in rats, including visuospatial performance and motivational processing \[[@ref038]\].•Moreover, in this article we have only discussed use of dopaminergic cells, whereas a stem cell source allows growth of any cell type. Other neural networks would be much more difficult to rebuild, but it is tempting to speculate that, for example, cholinergic cells could be helpful in addressing cognitive function, or balance.

There is a long road ahead in demonstrating how well stem cell-based reparative therapies will work, and much to understand about what, where, and how to deliver the cells, and to whom. But the massive strides in technology over recent years make it tempting to speculate that cell replacement may play an increasing role in alleviating at least the motor symptoms, if not others, in the decades to come
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